Krystal Biotech, Inc. — Director's Dealing 2017

Sep 25, 2017

SEC Form 3/A — Form 3/A

Issuer: Krystal Biotech, Inc. (KRYS)
CIK: 0001711279
Period of Report: 2017-09-19

Reporting Person: Sun Pharma (Netherlands) B.V. (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Convertible Preferred Stock	$		Common Stock (914107)		Direct

Footnotes

F1: The Series A convertible preferred stock will automatically convert on a one-to-one basis into 914,107 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering.

F2: These shares were incorrectly included in the Non-Derivative Securities table in the reporting person's original Form 3, filed September 19, 2017.